反应详情
EQUATION
反应方程式
REACTANTS
反应物
PRODUCTS
生成物
PROCEDURE
实验过程
Prepared analogously to Compound 3A using diethyl (4-{[4-({7-[1-(4-hydroxybutyl)-1H-pyrazol-4-yl]-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate (Compound 17B, 73 mg, 101 μmol) to afford 71 mg of the title compound (100%). 1H NMR (400 MHz, CD3OD) δ 8.49 (d, J=6.57 Hz, 1H), 8.23 (s, 1H), 8.04 (br. s., 1H), 7.77 (s, 2H), 7.57 (d, J=8.84 Hz, 1H), 7.11 (s, 1H), 6.95 (d, J=8.08 Hz, 1H), 4.42 (s, 2H), 4.22 (t, J=7.07 Hz, 2H), 3.82-3.92 (m, 5H), 3.59 (t, J=6.44 Hz, 2H), 3.07-3.11 (m, 3H), 3.03 (d, J=21, 2H), 1.97 (quin, J=7.33 Hz, 2H), 1.51-1.60 (m, 2H), 1.17 (t, J=7.07 Hz, 3H). MS (ESI): m/z 690.80 [M+H]+. UPLC: tR=1.07 min (UPLC-SQD: analytical—2 min).